KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Amortization of Deferred Charges for 14 consecutive years, with $653000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges fell 1.06% year-over-year to $653000.0, compared with a TTM value of $2.6 million through Dec 2025, down 21.94%, and an annual FY2025 reading of $2.6 million, down 21.94% over the prior year.
  • Amortization of Deferred Charges was $653000.0 for Q4 2025 at Biomarin Pharmaceutical, up from $649000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.1 million in Q3 2023 and bottomed at $649000.0 in Q3 2025.
  • Average Amortization of Deferred Charges over 5 years is $921600.0, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges crashed 80.28% in 2021, then grew 11.0% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $1.0 million in 2021, then fell by 0.39% to $1.0 million in 2022, then fell by 3.7% to $990000.0 in 2023, then tumbled by 33.33% to $660000.0 in 2024, then fell by 1.06% to $653000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for BMRN at $653000.0 in Q4 2025, $649000.0 in Q3 2025, and $660000.0 in Q2 2025.